SEC Form 4 · accession 0001140361-16-087477
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay Mazelsky
Officer — Executive Vice President
Period of report
Nov 18, 2016
Accepted (ET)
Nov 21, 2016 · 7:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 18, 2016 | M | 2,204 | $47.53 | A | 14,942 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right-to-buy)F3,F2 | $47.53 | Nov 18, 2016 | M | 2,204 | D | — | Aug 31, 2019 | Common Stock | 2,204 | 6,306 | D |
Explanation of responses
- F1Includes 63 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2016.
- F2Grant of option to buy 5,255 shares of IDEXX Laboratories, Inc. common stock that is exercisable in five annual installments of 1,051 shares each beginning on September 1, 2013, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F3Not applicable.